University of Texas's Southwestern Medical Center: Drug Shows Promise In Overcoming Endocrine Therapy Resistance In Breast Cancer
November 16, 2022
November 16, 2022
DALLAS, Texas, Nov. 16 (TNSjou) -- The University of Texas's Southwestern Medical Center issued the following news release:
For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to endocrine therapy. Now a preclinical study, led by researchers at UT Southwestern Medical Center, suggests that a class of new drugs already in clinical trials mig . . .
For patients with estrogen receptor (ER)-positive breast cancer, development of the so-called Y537S mutation signals that their disease has taken an aggressive course and may become resistant to endocrine therapy. Now a preclinical study, led by researchers at UT Southwestern Medical Center, suggests that a class of new drugs already in clinical trials mig . . .